Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications
Open Access
- 31 August 1989
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 60 (3) , 389-393
- https://doi.org/10.1038/bjc.1989.291
Abstract
The prognostic factors for response to chemotherapy and this prognostic impact of response status on survival, relative to other prognositc variables, were evaluated among 53 responding (9 complete responses; 44 partial responses) and 165 non-responding patients with inoperable adenocarcinoma of the lung (ACL). Multiple logistic regression analysis, including 27 pretreatment variables, revealed that the only significant predictor of response was bidimensionally measurable disease parameter (P=0.02), followed by brain metastases that were negatively correlated to response, although insignificantly (P=0.10). Univariate landmark analyses among patients alive at 8, 12, 16 and 24 weeks showed a trend towards better survival for responders compared with non-responders, but did not reach a significant level at any time (P values 0.78, 0.57, 0.23 and 0.12, respectively). Death hazard ratios for responders to non-responders were 0.91, 0.89, 0.79 and 0.73. Multivariate regression analysis among patients alive at 16 weeks demonstrated a significant impact on survival for performance status, non-radical tumour resection, liver metastases and LDH, while the impact of response status in comparison was weak and insignificant. This reflects the unsatisfactory treatment results achieved in inoperable ACL, with the majority of responses being partial, and calls for improvement of the cytostatic treatment currently available.This publication has 15 references indexed in Scilit:
- Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.Journal of Clinical Oncology, 1987
- Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.Journal of Clinical Oncology, 1986
- Differing Response Rates and Survival Between Squamous and Non-Squamous Non-Small Cell Lung Cancer Comparison of CAP Versus MAPAmerican Journal of Clinical Oncology, 1986
- Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V--a randomized comparison of four cisplatin-containing regimens.Journal of Clinical Oncology, 1985
- Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.Journal of Clinical Oncology, 1984
- Comparing survival of responders and nonresponders after treatment: A potential source of confusion in interpreting cancer clinical trialsControlled Clinical Trials, 1983
- Analysis of survival by tumor response.Journal of Clinical Oncology, 1983
- Commentary: current status of chemotherapy for non-small cell lung cancer.1981
- Evaluation of response criteria in advanced lung cancerCancer, 1979
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977